Karyopharm Therapeutics reported earnings of per KPTI share on Nov 11, 2026, falling short of analysts' expectations by
| Report Date | Nov 11, 2026 |
|---|---|
| Forecasted EPS | -$ 0.34 |
| Last Year's EPS | -$ 4.15 |
| EPS YoY Change |
Out of the last 58 earnings reporting periods, Karyopharm Therapeutics beat analysts’ expectations 29 times and fell short of expectations 23 time(s). Karyopharm Therapeutics reported earnings per share of in the last report surpassing an estimated EPS of -$ 0.34 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 11, 2026 | -$ 0.34 | -$ 4.32 | - | |
| Aug 13, 2026 | -$ 1.37 | -$ 2.32 | -$ 2.77 | |
| May 14, 2026 | -$ 1.45 | -$ 1.24 | -$ 3.60 | |
| Feb 12, 2026 | -$ 2.26 | -$ 5.68 | -$ 3.90 | |
| Nov 3, 2025 | -$ 3.47 | -$ 3.82 | -$ 3.00 | |
| Aug 11, 2025 | -$ 3.80 | -$ 4.32 | -$ 4.80 | |
| May 12, 2025 | -$ 4.21 | -$ 2.77 | -$ 5.40 | |
| Feb 19, 2025 | -$ 0.25 | -$ 3.60 | -$ 4.50 | |
| Nov 5, 2024 | -$ 3.94 | -$ 3.90 | -$ 4.35 | |
| Aug 6, 2024 | -$ 4.35 | -$ 3.00 | -$ 4.50 | |
| May 8, 2024 | -$ 4.95 | -$ 4.80 | -$ 0.43 | |
| Feb 29, 2024 | -$ 0.31 | -$ 5.40 | -$ 0.45 | |
| Nov 2, 2023 | -$ 4.20 | -$ 4.50 | -$ 0.62 | |
| Aug 2, 2023 | -$ 5.10 | -$ 4.35 | -$ 0.53 | |
| May 4, 2023 | -$ 0.37 | -$ 4.50 | $ 0.46 | |
| Feb 15, 2023 | -$ 0.35 | -$ 0.43 | -$ 0.69 | |
| Nov 3, 2022 | -$ 8.40 | -$ 0.45 | -$ 0.71 | |
| Aug 4, 2022 | -$ 9.45 | -$ 0.62 | -$ 0.77 | |
| May 5, 2022 | -$ 9.45 | -$ 0.53 | -$ 0.59 | |
| Feb 8, 2022 | -$ 6.00 | $ 0.46 | -$ 10.94 |
Karyopharm Therapeutics’s stock was trading at $ 0.0174 on Nov 10, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 11, 2026 | | $ 0.0174 | ||
| Aug 13, 2026 | -$ 2.32 | $ 2.03 | $ 2.02 | |
| May 14, 2026 | -$ 1.24 | $ 8.85 | $ 7.67 | |
| Feb 12, 2026 | -$ 5.68 | $ 7.37 | $ 8.58 | |
| Nov 3, 2025 | -$ 3.82 | $ 5.80 | $ 5.65 | |
| Aug 11, 2025 | -$ 4.32 | $ 3.94 | $ 4.02 | |
| May 12, 2025 | -$ 2.77 | $ 6.01 | $ 4.92 | |
| Feb 19, 2025 | -$ 3.60 | $ 9.45 | $ 9.15 | |
| Nov 5, 2024 | -$ 3.90 | $ 14.00 | $ 13.30 | |
| Aug 6, 2024 | -$ 3.00 | $ 13.07 | $ 12.17 | |
| May 8, 2024 | -$ 4.80 | $ 16.50 | $ 16.05 | |
| Feb 29, 2024 | -$ 5.40 | $ 19.95 | $ 17.77 | |
| Nov 2, 2023 | -$ 4.50 | $ 11.79 | $ 13.35 | |
| Aug 2, 2023 | -$ 4.35 | $ 27.00 | $ 27.15 | |
| May 4, 2023 | -$ 4.50 | $ 54.90 | $ 40.65 | |
| Feb 15, 2023 | -$ 0.43 | $ 49.80 | $ 53.85 | |
| Nov 3, 2022 | -$ 0.45 | $ 71.40 | $ 71.10 | |
| Aug 4, 2022 | -$ 0.62 | $ 67.50 | $ 70.20 | |
| May 5, 2022 | -$ 0.53 | $ 99.75 | $ 91.05 | |
| Feb 8, 2022 | $ 0.46 | $ 153.45 | $ 135.75 |
Karyopharm Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Karyopharm Therapeutics beat analysts’ expectations during the last earnings period by
